Skip to content

Opus Genetics IRD Adjustments to Additional Paid in Capital, Issuance Costs related to Common Stock, ATM and Registered Direct Financing

Adjustments to Additional Paid in Capital, Issuance Costs related to Common Stock, ATM and Registered Direct Financing at other companies

Richtech Robotics Inc. logo
Richtech Robotics Inc.RR
-$358.75K
Lightpath Technologies logo
Lightpath TechnologiesLPTH
$1.55M
Essential Utilities logo
Essential UtilitiesWTRG
-$12K-107%
SBA Communications logo
SBA CommunicationsSBAC
-$8.13M+33.6%
Adient logo
AdientADNT
$7M+75.0%
Gentherm logo
GenthermTHRM
$1.59M-62.9%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing.

The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's adjustments to additional paid in capital, issuance costs related to common stock, atm and registered direct financing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's adjustments to additional paid in capital, issuance costs related to common stock, ATM and registered direct financing?
Opus Genetics (IRD) reported adjustments to additional paid in capital, issuance costs related to common stock, ATM and registered direct financing of $186K in Q4 2025.
How has Opus Genetics's adjustments to additional paid in capital, issuance costs related to common stock, ATM and registered direct financing changed year-over-year?
Opus Genetics's adjustments to additional paid in capital, issuance costs related to common stock, ATM and registered direct financing increased by 14.1% year-over-year, from $163K to $186K.
What is the long-term trend for Opus Genetics's adjustments to additional paid in capital, issuance costs related to common stock, ATM and registered direct financing?
Over 2 years (2023 to 2025), Opus Genetics's adjustments to additional paid in capital, issuance costs related to common stock, ATM and registered direct financing has grown at a 162.9% compound annual growth rate (CAGR), from $136K to $940K.
What does adjustments to additional paid in capital, issuance costs related to common stock, ATM and registered direct financing mean?
Represents the costs incurred to issue equity, such as legal, accounting, and registration fees, which are recorded as a reduction to additional paid-in capital rather than as an operating expense. Tracking these adjustments is essential for understanding the net proceeds realized from equity financing activities.